慢性阻塞性肺疾病并呼吸衰竭患者血清甲状腺激素变化及临床意义.docVIP

慢性阻塞性肺疾病并呼吸衰竭患者血清甲状腺激素变化及临床意义 　　[摘要] 目的 探讨慢性阻塞性肺疾病（COPD）并呼吸衰竭患者血清甲状腺激素的变化及临床意义。方法 方便选取2015年6月―2016年6月收治的96例COPD并呼吸衰竭患者作为观察组，另选取80名健康者作为对照组，检测所有入选者血清甲状腺激素水平，记录检测结果。结果 观察组中COPD并呼吸衰竭急性期患者血清中TT3、TT4、FT3水平分别为（1.1±0.3）nmol/L、（96.1±32.6）nmol/L、（3.8±0.4）pmol/L，明显低于COPD并呼吸衰竭缓解期患者和对照组患者（P0.05）。观察组中死亡病例血清TT3、TT4、FT3、FT4水平分别为（0.8±0.1）nmol/L、（80.5±15.1）nmol/L、（2.4±0.9）pmol/L、（11.6±3.2）pmol/L，明显低于存活患者，差异有统计学意义（P0.05）。结论 COPD并呼吸衰竭患者血清TT3、TT4、FT3水平明显低于健康者，检测患者血清甲状腺激素水平变化对患者病情程度及预后评估具有一定的指导意义。 　　[关键词] 慢性阻塞性肺疾病；呼吸衰竭；甲状腺激素；临床意义 　　[中图分类号] R4 [文献标识码] A [文章编号] 1674-0742（2018）01（b）-0035-03 　　[Abstract] Objective To study the changes and clinical significance of serum thyroid hormone of patients with chronic obstructive pulmonary diseases and respiration failure. Methods 96 cases of patients with COPD and respiration failure from June 2015 to June 2016 were conveniently selected as the observation group， while 80 cases of healthy people were used as the control group， and the serum thyroid hormone level of all patients was tested and the test results were recorded. Results The serum TT3，TT4，FT3 levels in the observation group were respectively（1.1±0.3）nmol/L， （96.1±32.6）nmol/L，（3.8±0.4）pmol/L， which were obviously lower than the patients with COPD and respiration failure in the remission stage and patients in the control group（P0.05）， and the serum TT3，TT4，FT3，FT4 levels of death cases in the observation group were respectively（0.8±0.1）nmol/L，（80.5±15.1）nmol/L，（2.4±0.9）pmol/L、（11.6±3.2）pmol/L， which were obviously lower than the survival patients， and the differences were statistically significant（P0.05）. Conclusion The serum TT3，TT4，FT3 levels of patients with COPD and respiration medicine were obviously lower than those in the healthy patients， and the serum thyroid hormone level changes has a certain guidance significance to the severity of diseases and prognosis evaluation. 　　[Key words] Chronic obstructive pulmonary diseases； Respiration failure； Thyroid hormone； Clinical signif